A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis

Vaginitis Clinical Trial

Official title:
A Prospective, Open-Label, Comparative, Parallel Double-Arm, Multicentric Clinical Study to Evaluate the Efficacy of an Ovule With Triple Active Agents (Terconazole, Clindamycin, Fluocinolone) Administered Once Per Day for Three Days Versus an Ovule With Triple Active Agents (Metronidazole, Nystatin, Fluocinolone) Administered Once Per Day for Ten Days to Treat Secondary Vulvar/Vaginal Symptoms of Vaginitis/Infectious Vaginosis (Bacterial and/or Mycotic and/or Parasitic)

Status Completed

Clinical Trial Summary

The purpose of this comparative study is to evaluate the efficacy of an ovule with triple active agents (terconazole, clindamycin and fluocinolone) versus another ovule with triple active agents (nystatin, metronidazole and fluocinolone) in the treatment of symptoms caused by the presence of vaginitis (inflammation of the vagina) or bacterial vaginosis (polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli).

Clinical Trial Description

This is a prospective (study following participants forward in time), open-label (all people know the identity of the intervention), randomized (the study drug is assigned by chance), comparative, parallel (a clinical trial comparing the response in 2 or more groups of participants receiving different treatments) double-arm, multi-center (when more than 1 hospital or medical school team work on a medical research study) study. The study consists of 3 phases: Screening phase on Visit 1 (Day -3/1); Inclusion or treatment phase on Visit 2 (Day 1); and Treatment or monitoring phase (3 days after treatment) on Visit 3 (Day 7 for Gynoclin V and Day 13 for Vagitrol V) and Visit 4 (Day 12 for Gynoclin V and Day 18 for Vagitrol V). Participants will be randomly assigned to 1 of the 2 treatment groups: Gynoclin V and Vagitrol V. Participants in Gynoclin V group will be administered 1 ovule (containing 80 milligram [mg] terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide) vaginally every 24 hours at night, for 3 days. Participants in the Vagitrol V group will be administered 1 ovule (containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin) vaginally every 24 hours at night, for 10 days. Primarily, participants will be evaluated for signs and symptoms, characteristics of vaginal discharge, changes in vulvar region, changes in cervix and presence of bacteria, fungi and/or parasites. Participants' safety will be monitored throughout the study. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01867164
Study type	Interventional
Source	Janssen-Cilag, S.A.
Contact
Status	Completed
Phase	Phase 3
Start date	December 2007
Completion date	December 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02515656` - Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis	Phase 3
Recruiting	`NCT01420510` - Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis	Phase 2/Phase 3
Completed	`NCT04079218` - Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial	Phase 4
Recruiting	`NCT05557318` - Using Micro Electro Mechanical Systems to Detect the Air of Vaginal Discharge	N/A
Completed	`NCT01436513` - A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions.	Phase 1
Completed	`NCT03585049` - Microscopic Images for the Development of a Rapid Vaginitis Diagnostic Device
Completed	`NCT04676503` - Vaginal and Rectal Colonization of Lactobacillus Crispatus NTCVAG04 Following Oral Administration in Patients With History of Vaginitis/Vaginosis	N/A
Completed	`NCT02641717` - Validity of Patient-Collected Wet Mounts	N/A
Recruiting	`NCT05587283` - Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women	Phase 1
Not yet recruiting	`NCT06070454` - Prospective Evaluation of Infectious Vulvovaginitis on Wound Complication Rates After Vulvar Excision for Premalignant Lesions	N/A
Completed	`NCT02365389` - Once Daily In-situ Forming Versus Twice-daily Conventional Metronidazole Vaginal Gels for Treatment of Bacterial Vaginosis	Phase 2/Phase 3
Completed	`NCT01050465` - MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use	N/A
Completed	`NCT05652959` - Real-world Performance and Safety of Cerviron® in the Treatment of Vaginitis
Recruiting	`NCT02763696` - Establishment of a Sensitive System for Analysis of Child-bearing Women Vaginal Microbiota	N/A
Recruiting	`NCT04574089` - Treatment for Aerobic Vaginitis by Using Bofukang Vaginal Suppository	Phase 3
Recruiting	`NCT04816903` - Gyni™ Study With Leumit Health Services	N/A
Completed	`NCT05670535` - Sjögren and Gynecologic Considerations
Not yet recruiting	`NCT06438575` - Point of Care Diagnosis of Vaginal Infections	N/A
Enrolling by invitation	`NCT04984460` - Morphological Detection of Liquid-based Thin-layer Film-making Fungi for Fungal Vaginitis in Multiple Hospitals
Completed	`NCT03151928` - Diagnostic Accuracy By Providers Study